Brazil Contradicts Bharat Biotech Claim On Emergency Approval For Covaxin | Read
Controversy over a $324 million deal between Brazil and Bharat Biotech - for the import of 20 million doses of the 'made-in-India' COVID-19 vaccine Covaxin - continues to grow, with reports from the South American country saying its national health regulatory authority - ANVISA - had never actually granted the Hyderabad-based manufacturer an EUA (emergency use application).
